Kemper C A, Meng T C, Nussbaum J, Chiu J, Feigal D F, Bartok A E, Leedom J M, Tilles J G, Deresinski S C, McCutchan J A
Ann Intern Med. 1992 Mar 15;116(6):466-72. doi: 10.7326/0003-4819-116-6-466.
To determine the quantitative microbiologic response and the clinical response of patients with Mycobacterium avium complex bacteremia and AIDS to an oral antimycobacterial regimen.
A phase II, multicenter clinical trial.
Four university-affiliated medical centers.
Forty-one patients with HIV infection who had at least two consecutive blood cultures positive for M. avium complex and who had not received previous antimycobacterial therapy were enrolled in the study. Thirty-one patients were evaluable with regard to the efficacy of the oral regimen.
Patients received a combination of orally administered rifampin (600 mg), ethambutol (15 mg/kg body weight), clofazimine (100 mg once daily), and ciprofloxacin (750 mg twice daily) for 12 weeks. Parenterally administered amikacin, 7.5 mg/kg daily for 4 weeks after the first 4 weeks of oral therapy, was used at the discretion of the individual investigator.
Clinical symptoms, Karnofsky scores, and adverse events were monitored. Colony counts for M. avium complex were determined.
The mean logarithmic (log) baseline colony count decreased from 2.1 to 0.7 after 4 weeks of oral therapy (P less than 0.001). Suppression of bacteremia was sustained throughout therapy. Thirteen patients (42%) became culture negative during therapy. The mean duration of treatment was 9.7 weeks. Nineteen evaluable patients (61%) completed 12 weeks of therapy. Adverse reactions to one or more agents were common.
A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin. Colony counts rose dramatically after therapy was discontinued, suggesting that more prolonged periods of therapy are necessary to eradicate systemic infection.
确定鸟分枝杆菌复合体菌血症合并艾滋病患者对口服抗分枝杆菌治疗方案的微生物学定量反应及临床反应。
一项II期多中心临床试验。
四家大学附属医院医疗中心。
41例HIV感染患者,其至少连续两次血培养鸟分枝杆菌复合体阳性,且此前未接受过抗分枝杆菌治疗,被纳入研究。31例患者可评估口服治疗方案的疗效。
患者接受口服利福平(600毫克)、乙胺丁醇(15毫克/千克体重)、氯法齐明(每日100毫克)和环丙沙星(每日两次,每次750毫克)联合治疗12周。口服治疗前4周后,由个别研究者酌情使用每日7.5毫克/千克的阿米卡星静脉给药,持续4周。
监测临床症状、卡诺夫斯基评分及不良事件。测定鸟分枝杆菌复合体的菌落计数。
口服治疗4周后,平均对数基线菌落计数从2.1降至0.7(P<0.001)。整个治疗期间菌血症均得到持续抑制。13例患者(42%)在治疗期间血培养转为阴性。平均治疗时间为9.7周。19例可评估患者(61%)完成了12周治疗。对一种或多种药物的不良反应很常见。
使用利福平、乙胺丁醇、氯法齐明和环丙沙星口服治疗方案,早在治疗第2周即可迅速减轻症状和菌血症。治疗中断后菌落计数急剧上升,提示需要更长疗程的治疗以根除全身感染。